Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab)
Despite numerous publications on COVID-19, at present, conceptual thinking of the problem is only at a nascence stage. Treatment of patients with ANCA-associated systemic vasculitis (AAV) during the COVID-19 pandemic is one of the relevant issues. Management of COVID-19 in AAV patients undergoing an...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2020-09-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2937 |
| _version_ | 1797862589258006528 |
|---|---|
| author | T. V. Beketova L. M. Blank A. M. Lila |
| author_facet | T. V. Beketova L. M. Blank A. M. Lila |
| author_sort | T. V. Beketova |
| collection | DOAJ |
| description | Despite numerous publications on COVID-19, at present, conceptual thinking of the problem is only at a nascence stage. Treatment of patients with ANCA-associated systemic vasculitis (AAV) during the COVID-19 pandemic is one of the relevant issues. Management of COVID-19 in AAV patients undergoing anti-B cell therapy with rituximab (RTM) requires comprehensive reasoning. This paper presents a case report about COVID-19 in a 59-year-old female with AAV in remission, who was previously treated with RTM. COVID-19 was diagnosed one month after the last RTM administration; there were moderate bilateral pneumonia, fever, and extrapulmonary manifestations, including lesions of the gastrointestinal tract and central nervous system. Clinical outcome of COVID-19 was favorable, with no signs of respiratory failure, and CRP values did not exceed 29 mg/l. We discuss published data on RTM use during COVID-19 pandemic and the effects of B cells and their depletion on the course and outcomes of COVID-19. Our case report and available published data do not allow to consider RTM therapy as a factor associated with severe course of COVID-19 and adverse outcome. Further analysis of COVID-19 in patients with AAV and other rheumatic diseases is important. |
| first_indexed | 2024-04-09T22:23:06Z |
| format | Article |
| id | doaj.art-86eaa2aca51541b48614cd8b05de1bd1 |
| institution | Directory Open Access Journal |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| last_indexed | 2024-04-09T22:23:06Z |
| publishDate | 2020-09-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj.art-86eaa2aca51541b48614cd8b05de1bd12023-03-22T13:45:56ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922020-09-0158445646210.47360/1995-4484-2020-456-4622641Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab)T. V. Beketova0L. M. Blank1A. M. Lila2VA Nasonova Research Institute of RheumatologyVA Nasonova Research Institute of RheumatologyVA Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Prefessional Education, Ministry of Health of RussiaDespite numerous publications on COVID-19, at present, conceptual thinking of the problem is only at a nascence stage. Treatment of patients with ANCA-associated systemic vasculitis (AAV) during the COVID-19 pandemic is one of the relevant issues. Management of COVID-19 in AAV patients undergoing anti-B cell therapy with rituximab (RTM) requires comprehensive reasoning. This paper presents a case report about COVID-19 in a 59-year-old female with AAV in remission, who was previously treated with RTM. COVID-19 was diagnosed one month after the last RTM administration; there were moderate bilateral pneumonia, fever, and extrapulmonary manifestations, including lesions of the gastrointestinal tract and central nervous system. Clinical outcome of COVID-19 was favorable, with no signs of respiratory failure, and CRP values did not exceed 29 mg/l. We discuss published data on RTM use during COVID-19 pandemic and the effects of B cells and their depletion on the course and outcomes of COVID-19. Our case report and available published data do not allow to consider RTM therapy as a factor associated with severe course of COVID-19 and adverse outcome. Further analysis of COVID-19 in patients with AAV and other rheumatic diseases is important.https://rsp.mediar-press.net/rsp/article/view/2937covid-19rituximabb cellsancavasculitis |
| spellingShingle | T. V. Beketova L. M. Blank A. M. Lila Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab) Научно-практическая ревматология covid-19 rituximab b cells anca vasculitis |
| title | Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab) |
| title_full | Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab) |
| title_fullStr | Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab) |
| title_full_unstemmed | Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab) |
| title_short | Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab) |
| title_sort | covid 19 in a patient with anca associated systemic vasculitis receiving anti b cell therapy rituximab |
| topic | covid-19 rituximab b cells anca vasculitis |
| url | https://rsp.mediar-press.net/rsp/article/view/2937 |
| work_keys_str_mv | AT tvbeketova covid19inapatientwithancaassociatedsystemicvasculitisreceivingantibcelltherapyrituximab AT lmblank covid19inapatientwithancaassociatedsystemicvasculitisreceivingantibcelltherapyrituximab AT amlila covid19inapatientwithancaassociatedsystemicvasculitisreceivingantibcelltherapyrituximab |